COA documentation is available where applicable and may be viewed through the COA Reports page or requested from customer support.
While the efficacy data did not survive the Phase IIb primary endpoint, the safety dataset across 900 participants is unusual for a research peptide and is consistently cited as the basis for continued investigational interest
The patients anemia is due to chronic kidney disease stage 4. This link is the difference between a paid claim and a denied claim
View Protocol Complete dosage protocol and reconstitution guide for Semaglutide (10 mg Vial)
PubMed Stier, H., Amann, S., & Baumuller, M
BPC-157 shows promising results for lower back pain, particularly when inflammation and soft tissue damage are primary contributors